Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Synthetic Biologics Reports Results of Independent Third Party Evaluations of Trimesta™ Data from Investigator-Sponsored Phase 2 Clinical Trial for Relapsing-Remitting Multiple Sclerosis
Pregnancy outcomes in patients exposed to interferon beta-1b.
Genzyme’s Lemtrada Approved by the FDA
IgE-Mediated Allergic Reactions after the First Administration of Glatiramer Acetate in Patients with Multiple Sclerosis.
Pharmacology and therapeutic potential of interferons.
The OPTimization of interferon for MS study: 375 microg interferon beta-1b in suboptimal responders.
Natalizumab treatment during pregnancy - effects on the neonatal immune system.
FDA approval letter for daclizumab for the prophylaxis of acute organ rejection in patients receiving renal transplants
The effect of low-dose naltrexone on quality of life of patients with multiple sclerosis: a randomized placebo-controlled trial.
[Results of a comparative clinical trial of the Russian Β - interferon-1b bioanalogue (infibeta)].
More to come: humoral immune responses in MS.
Accentia Biopharmaceuticals Conducts Investigator Meeting in Preparation for New Multiple Sclerosis Drug Study for Cyrevia™
Childhood obesity and risk of pediatric multiple sclerosis and clinically isolated syndrome.
Takeda Pharmaceutical: New Drug Application Approval in Japan for Copaxone® Subcutaneous Injection 20 mg Syringe, a Drug for the Treatment of Multiple Sclerosis
Reviewing the Unmet Needs of Patients with Multiple Sclerosis.
The two faces of neuromyelitis optica.
Neuropathology of white matter disease in Leber's hereditary optic neuropathy.
Teva and Active Biotech remain committed to the development of NERVENTRA® (laquinimod) for multiple sclerosis following the negative opinion from the EMA's CHMP
Heterogeneity of serum gelatinases MMP-2 and MMP-9 isoforms and charge variants.
Sample-size calculations for short-term proof-of-concept studies of tissue protection and repair in multiple sclerosis lesions via conventional clinical imaging
Alerting Network Dysfunction in Early Multiple Sclerosis.
Low Dose Naltrexone: Side Effects and Efficacy in Gastrointestinal Disorders.
First-in-class thyrotropin-releasing hormone (TRH)-based compound binds to a pharmacologically distinct TRH receptor subtype in human brain and is effective in neurodegenerative models.
Daclizumab Therapy for Multiple Sclerosis.
Mechanical environment modulates biological properties of oligodendrocyte progenitor cells.

Pages